Healthy Clinical Trial
Official title:
Analysis of Cortical Biomarkers for Parkinson's Disease Patients
Previous studies revealed changes in the pattern of cortical electrical activity of patients with Parkinson's disease (PD) and suggested that these changes may be dependent on the phenotypes of the disease and other related factors. A greater understanding of cortical electrical activity in PD patients may be relevant to guide professionals about the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). The present study aims to evaluate the pattern of brain activity of PD patients and to correlate the findings with the disease phenotypes and with other clinical characteristics. For this, volunteers with PD and healthy will participate in a single experimental session in which behavioral and electrophysiological assessments will be performed.
Healthy individuals, after reading and signing the free and informed consent will be
submitted to a single session to obtain the normal neurophysiological and behavioral
endpoints and thus compare with those obtained in individuals with PD. All volunteers
(healthy and patients) will be submitted to a behavioral and neurophysiological evaluation
through transcranial magnetic stimulation (TMS) and electroencephalography (EEG).
The neurophysiological evaluation will be conducted during "ON" (with medication) and "OFF"
(without medication) period, by transcranial magnetic stimulation by single pulse (EMT-p) and
by EEG. TMS can perform different measures for the study of cortical excitability. The
analysis of the motor cortex excitability will be held by: (i) determination of motor
threshold (ii) the amplitude of the motor evoked potential (MEP). Since the assessment of the
cortex activity will be held by: (i) power spectrum density (PSD) of all frequencies bands.75
For evaluation with the TMS (Neurosoft - Russia) volunteers will be instructed to sit in a
chair and get comfortable position. Initially single TMS stimuli will be administered over
the motor cortex to determine the cortical representation area of the first dorsal
interosseous muscle (FDI) - MEP region whose response occurs more intensely observed by
electromyography. The electrodes with 10 mm diameter should be placed on the belly of the
target muscle and the reference electrode is placed in the interphalangeal joint of the
thumb. All care for the acquisition of electromyographic signal will be taken according to
the criteria of Surface Electromyography for the Non-invasive Assessment of Muscles (SENIAM).
For the location of the representative FDI muscle cortical region coil with an angle of 45
degrees is positioned at a distance of 20% of Cz point (according to the international system
for marking 10-20) bring into the contralateral muscle to be evaluated. For all evaluations
the same coil is used, the figure-eight angled in order to avoid measurement bias. To assess
cortical excitability of both hemispheres, the following measures are carried out: resting
motor threshold (RMT) and motor evoked potentials (MEP).
For EEG assessment, the electrodes will be positioned on the scalp of the individual,
according to the international 10-20 marking system, maintained with the maximum impedance of
10kΩ. During the acquisition of the electroencephalographic signal, a motor imagery and
execution protocol will be performed, in both upper limbs. The collected data will be further
processed and analyzed by MATLAB® software for Windows.
For behavioral assessment the following scales and tests will be performed during "ON" (with
medication) and "OFF" (without medication) period: Parkinson's disease sleep scale; Geriatric
Depression Scale; Edinburgh Handedness Inventory; International Physical Activity
Questionnaire; Timed up and go test; Berg Balance Scale; Unified Parkinson's disease Rating
Scale sessions II and III.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
| Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
| Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
| Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
| Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
| Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
| Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
| Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
| Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
| Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
| Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
| Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
| Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
| Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
| Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
| Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
| Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |